Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer

Autor:	Gemma Bruera, Eleonora Palluzzi, Enrico Ricevuto, Michela Pelliccione, Maria Vincenza Mancini, A. Santomaggio, Marianna Tudini, Corrado Ficorella, Paola Lanfiuti Baldi, Katia Cannita
Rok vydání:	2011
Předmět:	Oncology Male Cancer Research medicine.medical_specialty Organoplatinum Compounds medicine.medical_treatment GemOx Neutropenia Gastroenterology Deoxycytidine Pancreatic cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Aged Neoplasm Staging Aged 80 and over Chemotherapy Leukopenia business.industry General Medicine Middle Aged medicine.disease Survival Analysis Gemcitabine Oxaliplatin Pancreatic Neoplasms Treatment Outcome Tolerability Female medicine.symptom business medicine.drug
Zdroj:	Oncology reports. 27(2)
ISSN:	1791-2431
Popis:	The present study evaluated activity and toxicity of modulated doses of gemcitabine associated to oxaliplatin in patients with secondary CIRS and with locally advanced pancreatic adenocarcinoma (LAPC) and metastatic pancreatic adenocarcinoma (MPC). Since January 2006, untreated LAPC and MPC patients have been assessed with ADL, IADL, CIRS to modulate chemotherapy dosages according to co-morbidity stage. Patiens aged
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b56d81de055045be1458b126006f01ef https://pubmed.ncbi.nlm.nih.gov/22020810 Zobrazit plný text záznamu